The estimated Net Worth of Nicole D Perry is at least $224 mil dollars as of 2 August 2021. Ms. Perry owns over 1,000 units of Apellis Pharmaceuticals Inc stock worth over $224,291 and over the last 5 years she sold APLS stock worth over $0. In addition, she makes $0 as Vice President - Finance at Apellis Pharmaceuticals Inc.
Sign up
Ms. Perry APLS stock SEC Form 4 insiders trading
Nicole has made over 10 trades of the Apellis Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 1,000 units of APLS stock worth $3,760 on 2 August 2021.
The largest trade she's ever made was exercising 18,000 units of Apellis Pharmaceuticals Inc stock on 4 December 2020 worth over $67,680. On average, Nicole trades about 2,308 units every 19 days since 2020. As of 2 August 2021 she still owns at least 5,847 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Ms. Perry stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Nicole Perry biography
Nicole D. Perry is Vice President - Finance of the Company. Ms. Perry also served as Vice President of Finance at Revon. From August 2000 to April 2015, Ms. Perry worked as an independent consultant providing services to clients primarily in the areas of financial reporting, internal control compliance and as a liaison with external accountants, bankers and legal counsel. Prior to having her consulting practice, Ms. Perry worked in the audit practices of PricewaterhouseCoopers and Deloitte. Ms. Perry is a Certified Public Accountant and received her B.B.A. in accounting, with distinction, from the University of Oklahoma.
How old is Nicole Perry?
Nicole Perry is 55, she's been the Vice President - Finance of Apellis Pharmaceuticals Inc since 2016. There are 3 older and 19 younger executives at Apellis Pharmaceuticals Inc. The oldest executive at Apellis Pharmaceuticals Inc is Gerald Chan, 69, who is the Independent Chairman of the Board.
What's Nicole Perry's mailing address?
Nicole's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Insiders trading at Apellis Pharmaceuticals Inc
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois, ePascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
What does Apellis Pharmaceuticals Inc do?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
What does Apellis Pharmaceuticals Inc's logo look like?
Complete history of Ms. Perry stock trades at Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc executives and stock owners
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Cedric Francois,
President, Chief Executive Officer, Co-Founder, Director -
Lukas Scheibler,
Chief Innovation Officer -
Federico Grossi,
Chief Medical Officer -
Thomas Lackner,
Senior Vice President, Head of Europe -
Pascal Deschatelets,
Co-Founder, Chief Operating Officer -
Timothy Sullivan,
Chief Financial Officer, Treasurer -
Dr. Cedric Francois,
Co-Founder, Pres, CEO & Director -
Timothy E. Sullivan,
Chief Financial Officer -
Dr. Pascal Deschatelets Ph.D.,
Co-Founder & Chief Scientific Officer -
Adam J. Townsend,
Chief Commercial Officer -
Gerald Chan,
Independent Chairman of the Board -
Stephanie O'Brien,
Independent Director -
Alec Machiels,
Independent Director -
A. Sinclair Dunlop,
Independent Director -
Alec Machiels J.D., MBA,
Co-Founder & Independent Director -
Sam Martin,
IR Contact Officer -
Paul Fonteyne,
Independent Director -
Adam Townsend,
Chief Commercial Officer -
David Watson,
General Counsel, Vice President of Corporate Development -
Nicole Perry,
Vice President - Finance -
Victoria Brown,
Senior Vice President, Program Team Lead – Systemic Chronic -
David O. Watson,
Gen. Counsel -
Meredith Kaya,
Sr. VP, Investor Relations & Strategic Fin. -
James G. Chopas CPA,
VP, Corp. Controller & Chief Accounting Officer -
Dr. Lukas Scheibler M.D., Ph.D.,
Chief Innovation Officer -
Karen Lewis,
Chief People Officer -
Nur Nicholson,
Chief Technical Operations Officer -
Dr. Federico Grossi M.D., Ph.D.,
Co-Founder & Chief Medical Officer -
Nur Nicholson,
Chief Technical Officer -
Karen Lewis,
Chief People Officer -
Venture Investments Ltd Mor...,
10% owner -
Lucia Celona,
See Remarks -
Ahmad Sadr,
See Remarks -
Jeffrey Eisele,
Chief Development Officer -
Mark Jeffrey De Long,
Chief Business & Strat Officer -
James George Chopas,
VP/Chief Accounting Officer -
Caroline Baumal,
Chief Medical Officer